Cost Effectiveness of Ramipril in Patients at High Risk for Cardiovascular EventsEconomic Evaluation of the HOPE (Heart Outcomes Prevention Evaluation) Study for Germany from the Statutory Health Insurance Perspective

被引：0
|
作者：
Peter K. Schädlich
Josef Georg Brecht
Badrudin Rangoonwala
Eduard Huppertz
机构：
[1] InForMed GmbH — Outcomes Research and Health Economics,
[2] Bureau Itzehoe,undefined
[3] Aventis Pharma Deutschland GmbH,undefined
来源：
PharmacoEconomics | 2004年 / 22卷
关键词：
Ramipril; Target Variable; Statutory Health Insurance; Heart Outcome Prevention Evaluation; Microvascular Diabetic Complication;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Background: In the HOPE (Heart Outcomes Prevention Evaluation) trial, ramipril (compared with placebo) significantly reduced cardiovascular death and all-cause mortality as well as the incidence of costly cardiovascular events, such as myocardial infarction, revascularisation, stroke, cardiac arrest, hospitalisation due to heart failure and worsening angina pectoris, new-onset diabetes mellitus and microvascular diabetic complications.
引用
收藏
页码：955 / 973
页数：18
相关论文
共 50 条
  • [21] Reevaluation by high-performance liquid chromatography: Clinical significance of microalbuminuria in individuals at high risk of cardiovascular disease in the Heart Outcomes Prevention Evaluation (HOPE) study
    McQueen, Matthew J.
    Gerstein, Hertzel C.
    Pogue, Janice
    Mann, Johannes F. E.
    Yusuf, Salim
    AMERICAN JOURNAL OF KIDNEY DISEASES, 2006, 48 (06) : 889 - 896
  • [22] Exploring New Models for Cardiovascular Risk Reduction: The Heart Outcomes Prevention and Evaluation 4 (HOPE 4) Canada Pilot Study
    Schwalm, Jon -David
    Mccready, Tara
    Lear, Scott A.
    Lamelas, Pablo
    Garis, Len
    Musa, Hadi
    Vincent, Kaitey
    Islam, Shofiqul
    Attaran, Amir
    Mckee, Martin
    Yusuf, Salim
    CJC OPEN, 2021, 3 (03) : 267 - 275
  • [23] PLASMA RENIN ACTIVITY PREDICTS CARDIOVASCULAR EVENTS AND MORTALITY IN THE HEART OUTCOMES PREVENTION EVALUATION (HOPE) STUDY
    Verma, S.
    Gupta, M.
    Holmes, D. T.
    Xu, L.
    Teoh, H.
    Gupta, S.
    Yusuf, S.
    Lonn, E.
    CANADIAN JOURNAL OF CARDIOLOGY, 2010, 26 : 76D - 76D
  • [24] Sensitive and high sensitivity cardiac troponin I concentrations in the Heart Outcomes Prevention Evaluation (HOPE) study - A high risk population
    Kavsak, Peter A.
    McQueen, Matthew J.
    CLINICA CHIMICA ACTA, 2010, 411 (21-22) : 1832 - 1832
  • [25] Economic evaluation of Enoxaparin for anticoagulation in early Cardioversion of persisting nonvalvular atrial fibrillation:: A statutory health insurance perspective from Germany
    Schaedlich, Peter K.
    Schmidt-Lucke, Caroline
    Huppertz, Eduard
    Lehmacher, Walter
    Nixdorff, Uwe
    Stellbrink, Christoph
    Brecht, Josef Georg
    AMERICAN JOURNAL OF CARDIOVASCULAR DRUGS, 2007, 7 (03) : 199 - 217
  • [26] Economic evaluation of enoxaparin for anticoagulation in early cardioversion of persisting nonvalvular atrial fibrillation: A statutory health insurance perspective from Germany
    Schädlich P.K.
    Schmidt-Lucke C.
    Huppertz E.
    Lehmacher W.
    Nixdorff U.
    Stellbrink C.
    Brecht J.G.
    American Journal of Cardiovascular Drugs, 2007, 7 (3) : 199 - 217
  • [27] Impact of cigarette smoking in high-risk patients participating in a clinical trial. A substudy from the Heart Outcomes Prevention Evaluation (HOPE) trial
    Dagenais, GR
    Yi, OL
    Lonn, E
    Sleight, P
    Ostergren, J
    Yusuf, S
    EUROPEAN JOURNAL OF CARDIOVASCULAR PREVENTION & REHABILITATION, 2005, 12 (01): : 75 - 81
  • [28] Cost-Effectiveness of Ranibizumab for the Treatment of Neovascular Age-Related Macular Degeneration in Germany: Model Analysis From the Perspective of Germany's Statutory Health Insurance System
    Neubauer, Aljoscha S.
    Holz, Frank G.
    Sauer, Stefan
    Wasmuth, Timo
    Hirneiss, Christoph
    Kampik, Anselm
    Schrader, Wolfgang
    CLINICAL THERAPEUTICS, 2010, 32 (07) : 1343 - 1356
  • [29] Prevalence and determinants of microalbuminuria in high-risk diabetic and nondiabetic patients in the heart outcomes prevention evaluation study
    Gerstein, HC
    Mann, JFE
    Pogue, J
    Dinneen, SF
    Hallé, JP
    Hoogwerf, B
    Joyce, C
    Rashkow, A
    Young, J
    Zinman, B
    Yusuf, S
    DIABETES CARE, 2000, 23 : B35 - B39
  • [30] Cost effectiveness evaluation of cataract patient care in respect of monofocal intraocular lenses from the perspective of German statutory health insurances
    Landwehr, I
    Tehrani, M
    Dick, HB
    Krummenauer, F
    KLINISCHE MONATSBLATTER FUR AUGENHEILKUNDE, 2003, 220 (08) : 532 - 539
12345